What do systematic reviews say?

MBSR vs usual care

• Mindfulness‐based stress reduction for women diagnosed with breast cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 1094 participants
  Moderate

MBSR vs usual care

• Mindfulness‐based stress reduction for women diagnosed with breast cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 1097 participants
  Moderate

MBSR vs usual care

• Mindfulness‐based stress reduction for women diagnosed with breast cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 654 participants
  Moderate

MBSR vs usual care

The review found no eligible studies for this question.

• Mindfulness‐based stress reduction for women diagnosed with breast cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Tamoxifen vs placebo

Tamoxifen probably leads to lower overall breast cancer incidence compared with placebo (moderate certainty).

• Risk‐reducing medications for primary breast cancer: a network meta‐analysis 2019 · Cochrane Headline outcomes only
  RR 0.68 [0.62, 0.76]
  3 studies · 22832 participants
  Moderate

Tamoxifen vs placebo

Tamoxifen probably leads to higher severe toxicity compared with placebo (moderate certainty).

• Risk‐reducing medications for primary breast cancer: a network meta‐analysis 2019 · Cochrane Headline outcomes only
  RR 1.28 [1.12, 1.47]
  2 studies · 20361 participants
  Moderate

Aromatase inhibitors vs placebo

Aromatase inhibitors leads to lower overall breast cancer incidence compared with placebo (high certainty).

• Risk‐reducing medications for primary breast cancer: a network meta‐analysis 2019 · Cochrane Headline outcomes only
  RR 0.47 [0.35, 0.63]
  2 studies · 8424 participants
  High

Aromatase inhibitors vs placebo

Aromatase inhibitors leads to higher severe toxicity compared with placebo (high certainty).

• Risk‐reducing medications for primary breast cancer: a network meta‐analysis 2019 · Cochrane Headline outcomes only
  RR 1.18 [1.09, 1.28]
  2 studies · 8352 participants
  High

Aromatase inhibitors vs tamoxifen (indirect comparison)a

Aromatase inhibitors may leads to lower overall breast cancer incidence compared with tamoxifen (indirect comparison)a (low certainty).

• Risk‐reducing medications for primary breast cancer: a network meta‐analysis 2019 · Cochrane Headline outcomes only
  RR 0.67 [0.46, 0.98]
  5 studies · 31256 participants
  Low

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in overall survival ( compared with anthracyclines followed by taxane (moderate certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  HR 0.8 [0.6, 1.08]
  2 studies · 947 participants
  Moderate

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines leads to lower adverse events: neutropenia (grade 3/4) ( compared with anthracyclines followed by taxane (high certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 0.62 [0.4, 0.97]
  4 studies · 279 participants
  High

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in adverse events: neurotoxicity (grade 3/4) ( compared with anthracyclines followed by taxane (low certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 0.78 [0.25, 2.46]
  3 studies · 162 participants
  Low

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in treatment adherence (defined as dose delay) ( compared with anthracyclines followed by taxane (moderate certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 0.76 [0.52, 1.12]
  3 studies · 238 participants
  Moderate

Taxane followed by anthracyclines vs anthracyclines followed by taxane

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 20 participants
  Moderate

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in disease‐free survival ( compared with anthracyclines followed by taxane (moderate certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  HR 0.84 [0.65, 1.09]
  1 study · 828 participants
  Moderate

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in pathological complete response (no invasive cancer in breast or… compared with anthracyclines followed by taxane (high certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 1.15 [0.96, 1.38]
  4 studies · 1280 participants
  High

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in adverse events: neutropenia (grade 3/4) ( compared with anthracyclines followed by taxane (moderate certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 1.25 [0.86, 1.82]
  1 study · 280 participants
  Moderate

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in adverse events: neurotoxicity (grade 3/4) ( compared with anthracyclines followed by taxane (low certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 0.95 [0.55, 1.65]
  2 studies · 1108 participants
  Low

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in treatment adherence (defined as dose reduction) ( compared with anthracyclines followed by taxane (moderate certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 0.81 [0.59, 1.11]
  1 study · 280 participants
  Moderate

Taxane followed by anthracyclines vs anthracyclines followed by taxane

The review found no eligible studies for this question.

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found